GLP-1 Weight Loss Therapy

Clinically supervised GLP-1 receptor agonist therapy (semaglutide or liraglutide) for medically indicated weight loss, combined with nutrition support and regular physician monitoring.

Minmed Group offers medically supervised GLP-1 receptor agonist therapy as part of its Medical Weight Management programme for patients who meet clinical eligibility criteria. GLP-1 (glucagon-like peptide-1) medications mimic a natural gut hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity — making them among the most clinically proven pharmacological tools for obesity management available today. Commonly prescribed GLP-1 agents include semaglutide (the active ingredient in Ozempic and Wegovy) and liraglutide (Saxenda). Both are administered by subcutaneous injection — semaglutide typically once weekly and liraglutide once daily — and are titrated gradually upward over several weeks to maximise tolerability and therapeutic effect. At Minmed, the prescribing physician conducts a thorough pre-treatment assessment to confirm suitability for GLP-1 therapy: ruling out contraindications such as personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, or severe gastrointestinal disease. Blood tests review fasting glucose, HbA1c, lipid profile, and renal and liver function to establish a baseline and identify any concurrent metabolic conditions that GLP-1 therapy may also benefit. The typical patient profile is an adult with a BMI of 27 kg/m² or above with at least one weight-related comorbidity (such as pre-diabetes, type 2 diabetes, hypertension, or dyslipidaemia), or a BMI of 30 kg/m² or above without additional risk factors. GLP-1 therapy is prescribed alongside a structured nutrition and lifestyle programme — not as a standalone solution — to maximise outcomes and build the habits needed to maintain results. Large-scale clinical trials (SUSTAIN-6, SCALE, STEP) have demonstrated 10–18% mean body weight reduction with semaglutide and liraglutide respectively over 68–72 weeks, along with improvements in glycaemic control, blood pressure, and cardiovascular risk markers. Minmed's physicians interpret these results in the context of each patient's individual health profile and goals. Monthly follow-up appointments track weight, metabolic parameters, and any side effects (most commonly mild nausea, vomiting, or constipation during dose escalation). The programme includes a tapering plan when the patient approaches their weight goal to preserve results after medication discontinuation.